Hemogenyx Pharmaceuticals (LON: HEMO) has received clearance from its independent Data Safety Monitoring Board (DSMB) to proceed to the next adult dose level in its Phase I clinical trial of
Hemogenyx Pharmaceuticals (LON: HEMO) Letter of Intent with Cellin Technologies
Hemogenyx Pharmaceuticals Signs Letter of Intent with Cellin Technologies to Advance Commercialization of HG-CT-1 CAR-T Therapy in Estonia First Potential Near-Term Revenue Opportunity
Hemogenyx Shares Surge 26% on Positive Phase I CAR-T Trial Update for AML
Hemogenyx Pharmaceuticals has announced encouraging progress in its Phase I clinical trial of HG-CT-1, a CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML) in adults.
Hemogenyx Pharma Plc (LON:HEMO) Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing
Hemogenyx Pharmaceuticals Awarded G-Rex® Grant to Support Scalable, Cost-Optimized CAR-T Manufacturing
Hemogenyx Pharma Plc (LON:HEMO) Second Patient Passes Initial Safety Tests
Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation
Hemogenyx Pharma Plc (LON:HEMO) Second Patient Treated with HG-CT-1 CAR-T Therapy
Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that the second patient has been successfully treated as part of the Company’s ongoing Phase I clinical trial of HG-CT-1, its
Hemogenyx Pharma Plc (LON:HEMO) First-in-Human leukaemia treatment with HG-CT-1
First-in-Human Treatment with HG-CT-1 for Relapsed or Refractory Acute Myeloid Leukemia
Hemogenyx Pharma Plc (LON:HEMO) announced a “major milestone” by launching its first trial site
Hemogenyx Pharmaceuticals PLC (LSE: HEMO, OTC: HOPHF) announced a “major milestone” by launching its first trial site and beginning patient recruitment for the clinical trial of its flagship drug, which
Hemogenyx Pharma Plc (LON:HEMO) Ultrafast CAR-T Manufacturing
Hemogenyx Pharmaceuticals PLC (LSE: HEMO, OTC: HOPHF), a UK-listed biopharmaceutical company specializing in blood cancer treatments, has partnered with Kure.ai to develop an ultrafast manufacturing process for its CAR-T cell
Hemogenyx Pharma Plc (LON:HEMO) IRB Approval for Phase I Clinical Trial
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)
Hemogenyx Pharma Plc (LON:HEMO) Strategic Investment from Prevail Partners, LLC
Strategic Investment from Prevail Partners, LLC
Hemogenyx Pharmaceuticals (LON:HEMO) prepares for Phase I trial.
Hemogenyx Pharmaceuticals PLC (LSE: HEMO, OTC: HOPHF) announced that it is in the final stages of establishing a clinical site for a Phase I trial of its lead asset, HEMO-CAR-T,